Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Opvallende observationele data over MS-behandeling in Duitsland
okt 2018 | Multipele Sclerose